Immunogen (IMGN) Tops Q4 EPS by 26c, Offers Q1 Guidance

Immunogen (NASDAQ: IMGN) reported Q4 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $85.8 million versus the consensus estimate of $37.09 million.

GUIDANCE:

Immunogen sees Q1 2021 revenue of $65-75 million, versus the consensus of $53.1 million.

• operating expenses between $200 million and $210 million; and
• cash and cash equivalents at December 31, 2021 to be between $140 million and $150 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c